Singular analogues and prices. Singulair's analogues: a list of cheap and effective drugs Singular's analogues are cheaper

Bronchospasm is a phenomenon familiar to patients suffering from asthma. Against the background of obstructed bronchial patency, increased sputum production is observed, and the number of eosinophils increases. Symptoms of seasonal and year-round allergic rhinitis are swelling of the mucous membrane of the nasopharynx, tearing, headache, runny nose, itching, sneezing.

The American drug Singular "turns off" cysteinyl leukotriene receptors in the epithelium of the patient's respiratory organs, and also effectively relieves bronchospasm. The active ingredient in the medicine is montelukast.

The scope of the drug includes the prevention of bronchospasm, the treatment of bronchial asthma in children and adults, as well as the treatment of seasonal and regular allergic rhinitis. For children, the drug is allowed from 6 years. Release form - tablets, chewable tablets.

The tool is expensive, prices are in the range of 1000-1300 rubles per package with 14 tablets. Cheap analogues of the drug Singular contain the same active ingredient or have similar indications for use.

Analogues of Russian production

Close substitutes for the Russian-made Singular are a quality replacement for a cheap drug with montelukast. The table contains a list of similar products with prices and brief characteristics.

Name of the drug	Average price in rubles	Characteristic
Moncasta	750–840	Chewable tablets with montelukast, causing bronchodilation as early as 2 hours after consumption. They are used to stop attacks of bronchial asthma, with rhinitis of allergic origin.
Montelukast	520–750	The tool has indications and contraindications for use similar to the singular.
Ectalust	440–520	The cheapest synonym for the singular from a domestic manufacturer. The composition of the drug includes montelukast.

Ukrainian substitutes

Ukrainian-made medicines can be a worthy replacement for the singular. Their cost is cheaper than the drug in question.

Medicines belong to the pharmacological group of drugs for the treatment of obstructive diseases of the respiratory system, although not all drugs from the list contain montelukast.

Montel. Inexpensive Ukrainian analogue with the same active ingredient. The drug is used to treat seasonal allergic rhinitis, bronchial asthma of varying severity. Available in the form of regular pills and chewable. The average price is 450–490 rubles.
Allergomax. Medication in the form of syrup, nasal spray or tablets. The drug effectively eliminates the symptoms of allergic rhinitis - lacrimation, itching, swelling, headache. The average price is 56–90 rubles.
Bronchomax. Syrup or tablets with fenspiride hydrochloride. The drug is indicated for otitis, sinusitis, rhinitis, including allergic, bronchitis. The drug is also used in the treatment of bronchial asthma. The average price is 95–140 rubles.
Teopak. Anti-asthma drug with theophylline in the base. Pills are taken for bronchial asthma, pulmonary emphysema, obstructive bronchitis.
Contraindications include children under 14 years of age, pregnancy, breastfeeding, convulsive conditions, acute myocardial infarction, hyperthyroidism. The average price is 45-60 rubles.

Belarusian generics

The table united modern Belarusian generics of the singular. Anti-asthma drugs are not its exact analogues, but are characterized by similar indications for use.

Name of the drug	Average price in rubles	Characteristic
Eufillin	15–35	A bronchodilator that relaxes the muscles of the bronchi. The drug effectively stops bronchospasm. In the instructions for the drug, the indications list bronchial asthma, obstructive bronchitis, Pickwick's syndrome, chronic cor pulmonale.
beclomethasone	330–380	Anti-asthma drug used in the treatment of bronchial asthma for adults and children over 6 years of age. Release form - aerosol for inhalation.
Celeflu	330–400	The aerosol is used in the therapeutic treatment of mild, moderate and severe asthma. Not intended to relieve acute asthma symptoms.

Other foreign analogues

Singular import synonyms will help you choose what to replace the singular with. The list is below.

Singlon. The best substitute for Singulair with the same principle of action and active substance. The tool has similar indications for use. Country of origin - Hungary. The average price is 440–870 rubles.
Montelar. The drug is produced in Switzerland, Turkey, Slovenia. The active substance is montelukast. The average price is 440–1050 rubles.
Montler. The release form of the drug is chewable tablets. Country of origin - Croatia. The average price is 240-440 rubles.
Almont. It is used for asthma and allergic rhinitis. The drug is manufactured in Switzerland. The average price is 700–960 rubles.
Montelast. A close substitute for Singular with a similar active ingredient. Sold in tablets. The tool is produced in Switzerland, in Malta. The average price is 640–2600 rubles.

Singulair and its analogues are popular drugs in the treatment of diseases indicated in the instructions.

Allergic rhinitis, like bronchial asthma, is a formidable disease that, in extreme cases, can lead to conditions that are incompatible with life, so they cannot be ignored. Montelukast is an effective substance that can not only treat, but also prevent dangerous symptoms.

Active substance

Montelukast (montelukast)

Release form, composition and packaging

Chewable tablets pink, oval, biconvex, with "SINGULAIR" embossed on one side and "MSD 711" on the other.

Excipients: mannitol - 161.08 mg, microcrystalline cellulose - 52.8 mg, hyprolose (hydroxypropylcellulose) - 7.2 mg, iron oxide red - 0.36 mg, croscarmellose sodium - 7.2 mg, cherry flavor - 3.6 mg, aspartame - 1.2 mg, magnesium stearate - 2.4 mg.

7 pcs. - blisters (1) - packs of cardboard.
7 pcs. - blisters (2) - packs of cardboard.
7 pcs. - blisters (4) - packs of cardboard.

pharmachologic effect

Leukotriene receptor antagonist. Cysteinyl leukotrienes LTC 4 , LTD 4 , LTE 4 are strong inflammatory mediators - eicosanoids, which are secreted by various cells, incl. mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors. Cysteinyl leukotriene type I receptors (CysLT 1 receptors) are present in the human airways (including bronchial smooth muscle cells, macrophages) and other pro-inflammatory cells (including eosinophils and some myeloid stem cells). Cysteinyl leukotrienes correlate with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchospasm, increased mucus secretion, increased vascular permeability, and increased eosinophil counts. In allergic rhinitis, post-exposure release of cysteinyl leukotrienes from pro-inflammatory cells of the nasal mucosa during the early and late phases of the allergic reaction is manifested by the symptoms of allergic rhinitis. An intranasal test with cysteinyl leukotrienes demonstrated an increase in airway resistance and symptoms of nasal obstruction.

Montelukast is a highly potent oral drug that significantly improves inflammation in asthma. According to biochemical and pharmacological analysis, montelukast binds with high affinity and selectivity to CysLT 1 receptors, without interacting with other pharmacologically important receptors in the respiratory tract (such as prostaglandin receptors, cholino- or β-adrenergic receptors). Montelukast inhibits the physiological action of cysteinyl leukotrienes LTC 4 , LTD 4 , LTE 4 by binding to CysLT 1 receptors without stimulating these receptors.

Montelukast inhibits CysLT receptors in the respiratory tract, as evidenced by the ability to block the development of bronchospasm in response to inhalation of LTD 4 in patients with bronchial asthma. Doses of 5 mg are sufficient to relieve bronchospasm induced by LTD 4 .

Montelukast causes bronchodilation within 2 hours of oral administration and may supplement bronchodilation induced by β2-adrenergic agonists.

The use of montelukast in doses of more than 10 mg / day once does not increase the effectiveness of the drug.

Pharmacokinetics

Suction

After oral administration, montelukast is rapidly and almost completely absorbed. Regular meals do not affect Cmax in the blood and the bioavailability of chewable tablets. In children aged 2 to 5 years, after taking 4 mg chewable tablets on an empty stomach, Cmax is reached after 2 hours.

The pharmacokinetics of montelukast remains almost linear when taken orally at doses greater than 50 mg.

When taking montelukast in the morning and evening, no differences in pharmacokinetics are observed.

Distribution

The binding of montelukast to plasma proteins is more than 99%. V d in the equilibrium state is 8-11 liters.

Studies conducted on rats with radiolabeled montelukast indicate minimal penetration through the BBB. In addition, the concentration of labeled montelukast 24 hours after administration was minimal in all other tissues.

When taking montelukast at a dose of 10 mg 1 time / day, a moderate (about 14%) accumulation of the active substance in plasma is observed.

Metabolism

Montelukast is actively metabolized. When used in therapeutic doses, the concentration of montelukast metabolites in plasma in an equilibrium state in adults and children is not determined.

In vitro studies using human liver microsomes have shown that isoenzymes of the cytochrome P450 system: CYP3A4, 2C8 and 2C9 are involved in the metabolism of montelukast. According to the results of studies conducted in vitro on human liver microsomes, montelukast at therapeutic concentration in blood plasma does not inhibit CYP3A4, 2C9, 1A2, 2A6, 2C19 and 2D6 isoenzymes.

breeding

T 1/2 of montelukast in young healthy adults ranges from 2.7 to 5.5 hours. Plasma clearance of montelukast in healthy adults averages 45 ml / min. After ingestion of radiolabeled montelukast, 86% is excreted in the feces within 5 days and less than 0.2% in the urine, which confirms that montelukast and its metabolites are excreted almost exclusively in the bile.

Pharmacokinetics in special clinical situations

The pharmacokinetics of montelukast in women and men is similar.

With a single oral dose of montelukast at a dose of 10 mg, the pharmacokinetic profile and bioavailability are similar in elderly and young patients. In the elderly, T 1/2 of montelukast from plasma is somewhat longer. Dose adjustment in elderly patients is not required.

There were no differences in clinically significant pharmacokinetic effects in patients of different races.

In patients with mild to moderate hepatic insufficiency and clinical manifestations of liver cirrhosis, a slowdown in the metabolism of montelukast was noted, accompanied by an increase in AUC of approximately 41% after a single dose of the drug at a dose of 10 mg. The excretion of montelukast in these patients is slightly increased compared with healthy subjects (mean T 1/2 - 7.4 h). Changes in the dose of montelukast for patients with mild to moderate hepatic insufficiency are not required. Data on the nature of the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (more than 9 points on the Child-Pugh scale).

Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast have not been evaluated in patients with renal insufficiency. Dose adjustment in this category of patients is not required.

Indications

- prevention and long-term treatment of bronchial asthma in children aged 2 years and older: in order to control daytime and nighttime symptoms of the disease;

Relief of symptoms of allergic rhinitis in children aged 2 years and older.

Contraindications

- children's age up to 2 years;

- phenylketonuria;

- Hypersensitivity to the components of the drug.

Dosage

Inside 1 time / day, regardless of the meal.

For treatment bronchial asthma Singulair should be taken in the evening.

During treatment allergic rhinitis the drug can be taken at any time of the day at the request of the patient.

Patients with bronchial asthma and allergic rhinitis should take 1 tablet of the drug Singulair 1 time per day in the evening.

Children aged 2 to 5 years

With bronchial asthma and / or allergic rhinitis- 1 chewable tablet 4 mg per day.

The therapeutic effect of the drug Singulair on indicators reflecting the course of bronchial asthma develops during the first day. The patient should continue to take Singular both during the period of achieving control of the symptoms of bronchial asthma, and during periods of exacerbation of bronchial asthma.

For elderly patients, patients with renal insufficiency, as well as patients with mild or moderate hepatic impairment, and also depending on gender, a special dose selection is not required.

The appointment of the drug Singulair simultaneously with other types of treatment for bronchial asthma

Singulair can be added to the patient's treatment with bronchodilators and inhaled corticosteroids.

Side effects

In general, Singulair is well tolerated by patients. Side effects are usually mild and usually do not require discontinuation of the drug. The overall frequency of side effects in the treatment of the drug Singulair is comparable to their frequency when taking placebo.

Children aged 2 to 5 years with asthma

In clinical studies of the drug Singulair, 573 patients aged 2 to 5 years took part. In a 12-week placebo-controlled clinical trial, the only adverse event (AE) assessed as drug-related occurring in >1% of patients taking Singulair and more frequently than in the placebo group was thirst. Differences in the incidence of this AE between the two treatment groups were not statistically significant.

In total, in the studies, 426 patients aged 2 to 5 years were treated with Singulair for at least 3 months, 230 for 6 months or more, and 63 patients for 12 months or more. With longer treatment, the AE profile did not change.

Children aged 2 to 14 with seasonal allergic rhinitis

In a 2-week placebo-controlled clinical trial using Singulair for the treatment of seasonal allergic rhinitis, 280 patients aged 2 to 14 years participated. Patients took Singulair 1 time / day in the evening and were generally well tolerated. The safety profile of the drug in children was similar to that of placebo. In this clinical study, there were no AEs that were regarded as drug-related, were observed in ≥1% of patients taking Singulair, and more often than in the placebo group.

Children aged 6 to 14 with asthma

The safety profile of the drug in children was generally similar to that in adults and comparable to that of placebo.

In an 8-week placebo-controlled clinical trial, the only AE assessed as drug-related occurring in >1% of Singulair patients and more frequently than in the placebo group was headache. The difference in frequency between the two treatment groups was not statistically significant.

In growth rate studies, the safety profile in patients of this age group was consistent with the previously described safety profile of Singulair.

With longer treatment (more than 6 months), the AE profile did not change.

Adults and children aged 15 years and older with asthma

In two similarly designed, 12-week placebo-controlled clinical trials, the only AEs assessed as drug-related occurring in ≥1% of patients taking Singulair and more frequently than in the placebo group were abdominal pain and headache. pain. Differences in the frequency of these AEs between the two treatment groups were not statistically significant. With longer treatment (within 2 years), the AE profile did not change.

Adults and children 15 years of age and older with seasonal allergic rhinitis

Patients took Singulair 1 time / day in the morning or in the evening, in general, the drug was well tolerated, the safety profile of the drug was similar to that of placebo. In placebo-controlled clinical trials, there were no AEs that were regarded as drug-related, were observed in ≥1% of patients taking Singulair, and more often than in the placebo group. In a 4-week placebo-controlled clinical study, the safety profile of the drug was similar to that in 2-week studies. The incidence of drowsiness when taking the drug in all studies was the same as when taking placebo.

Adults and children 15 years of age and older with perennial allergic rhinitis

Patients took Singular 1 time / day in the morning or in the evening, in general, the drug was well tolerated. The safety profile of the drug was similar to the safety profile observed in the treatment of patients with seasonal allergic rhinitis and placebo. In these clinical studies, there were no AEs that would be regarded as drug-related, were observed in ≥1% of patients taking Singulair, and more often than in the placebo group. The incidence of drowsiness when taking the drug was the same as when taking placebo.

Generalized analysis of the results of clinical studies

A pooled analysis of 41 placebo-controlled clinical trials (35 trials in patients aged 15 years and older, 6 trials in patients aged 6 to 14 years) was performed using validated methods for assessing suicidality. Among 9929 patients who received Singulair and 7780 patients who received placebo in these studies, 1 patient with suicidal ideation was identified in the group of patients who received Singulair. None of the treatment groups experienced any suicide, suicide attempt, or other preparatory actions indicative of suicidal behavior.

Separately, a pooled analysis of 46 placebo-controlled clinical trials (35 trials in patients aged 15 years and older; 11 trials in patients aged 3 months to 14 years) was performed to evaluate adverse behavioral effects. Among the 11,673 patients who took Singulair in these studies and 8827 patients who took placebo, the percentage of patients who had at least one adverse behavioral effect was 2.73% among patients who received Singular and 2.27% among patients who received placebo; the odds ratio was 1.12 (95% confidence interval).

AEs registered during post-registration use of the drug

From the side of the blood coagulation system: increased tendency to bleed.

From the immune system: hypersensitivity reactions, incl. anaphylaxis; very rarely (<1/10 000) - эозинофильная инфильтрация печени.

From the side of the psyche: agitation (including aggressive behavior or hostility), anxiety, depression, disorientation, impaired attention, abnormal dreams, hallucinations, insomnia, memory impairment, psychomotor activity (including irritability, restlessness and tremor), somnambulism, suicidal thoughts and behavior ( suicidality).

From the nervous system: dizziness, drowsiness, paresthesia/hypesthesia; very rarely (<1/10 000) - судороги.

From the side of the cardiovascular system: cardiopalmus.

From the respiratory system: nosebleeds, pulmonary eosinophilia.

From the digestive system: diarrhea, dyspepsia, nausea, vomiting, pancreatitis.

From the side liver and biliary tract: increased activity of ALT and ACT in the blood; very rarely (<1/10 000) - гепатит (включая холестатические, гепатоцеллюлярные и смешанные поражения печени).

From the skin and subcutaneous tissues: tendency to form hematomas, erythema nodosum, erythema multiforme, itching, rash.

Allergic reactions: angioedema, urticaria.

From the musculoskeletal system: arthralgia, myalgia, including muscle cramps.

From the urinary system: enuresis in children.

General reactions: asthenia (weakness)/fatigue, edema, pyrexia.

Overdose

Symptoms overdoses have not been identified in clinical studies of long-term (22 weeks) treatment with Singular in adult patients with bronchial asthma at doses up to 200 mg / day, or in short (about 1 week) clinical studies when taking the drug at doses up to 900 mg / day.

There have been cases of acute overdose of the drug Singulair (taking at least 1000 mg / day) in the post-registration period and during clinical trials in adults and children. Clinical and laboratory data indicated comparability of the safety profiles of the drug Singulair in children, adults and elderly patients. The most common symptoms were thirst, drowsiness, vomiting, psychomotor agitation, headache, and abdominal pain. These side effects are consistent with the safety profile of Singulair.

Treatment: conducting symptomatic therapy. There is no specific information on the treatment of overdose with Singulair. There are no data on the effectiveness of peritoneal dialysis or hemodialysis of montelukast.

drug interaction

Singulair can be administered together with other drugs traditionally used for the prevention and long-term treatment of bronchial asthma and/or the treatment of allergic rhinitis. Montelukast at the recommended therapeutic dose did not have a clinically significant effect on the pharmacokinetics of the following drugs: prednisone, prednisone, oral contraceptives (ethinyl estradiol / norethindrone 35/1), terfenadine, digoxin and warfarin.

With the simultaneous administration of phenobarbital, the AUC value of montelukast decreases by approximately 40%. , but this does not require changes in the dosing regimen of the drug Singulair.

In vitro studies have shown that montelukast inhibits the CYP2C8 isoenzyme. However, in the study of in vivo drug interactions of montelukast and rosiglitazone (metabolized with the participation of the CYP2C8 isoenzyme), no confirmation of inhibition of the CYP2C8 isoenzyme by montelukast was obtained. Therefore, in clinical practice, the effect of montelukast on the CYP2C8-mediated metabolism of a number of drugs is not expected, incl. paclitaxel, rosiglitazone, repaglinide.

In vitro studies have shown that montelukast is a substrate of CYP2C8, 2C9 and 3A4 isoenzymes. Data from a clinical drug interaction study between montelukast and gemfibrozil (an inhibitor of both CYP2C8 and 2C9) demonstrate that gemfibrozil increases the effect of systemic exposure to montelukast by 4.4 times. Co-administration of itraconazole, a potent inhibitor of CYP3A4, with gemfibrozil and montelukast did not lead to an additional increase in the effect of systemic exposure to montelukast. The effect of gemfibrozil on the systemic exposure of montelukast cannot be considered clinically significant based on safety data when used at doses greater than the approved dose of 10 mg for adult patients (for example, 200 mg/day for adult patients for 22 weeks and up to 900 mg/day for patients taking the drug for approximately one week, there were no clinically significant adverse effects). Thus, when co-administered with gemfibrozil, dose adjustment of montelukast is not required. Based on the results of in vitro studies, no clinically significant drug interactions with other known inhibitors of CYP2C8 (eg, trimethoprim) are expected. In addition, the co-administration of montelukast with itraconazole alone did not lead to a significant increase in the effect of systemic exposure to montelukast.

Combination treatment with bronchodilators

Singular is a reasonable adjunct to monotherapy with bronchodilators if the latter do not provide adequate control of bronchial asthma. Upon reaching a therapeutic effect from treatment with Singulair, a gradual reduction in the dose of bronchodilators can be started.

Combined treatment with inhaled corticosteroids

Treatment with Singulair provides an additional therapeutic effect in patients using inhaled corticosteroids. Upon reaching stabilization of the condition, you can begin a gradual reduction in the dose of corticosteroids under the supervision of a physician. In some cases, the complete abolition of inhaled corticosteroids is acceptable, but a sharp replacement of inhaled corticosteroids with Singulair is not recommended.

special instructions

The efficacy of oral Singulair in the treatment of acute asthma attacks has not been established. Therefore, Singular tablets are not recommended for the treatment of acute attacks of bronchial asthma. Patients should be instructed to carry emergency asthma medications (short-acting inhaled beta2-agonists) with them at all times.

Do not stop taking Singulair during an asthma exacerbation and the need to use emergency drugs (short-acting inhaled beta 2-agonists) to stop attacks.

Patients with confirmed allergy to and other NSAIDs should not take these drugs during treatment with Singulair, since Singulair, while improving respiratory function in patients with allergic bronchial asthma, however, cannot completely prevent bronchoconstriction caused by NSAIDs.

The dose of inhaled glucocorticosteroids used simultaneously with Singulair can be gradually reduced under the supervision of a physician, however, abrupt replacement of inhaled or oral glucocorticosteroids with Singulair should not be carried out.

Psychoneurological disorders have been described in patients taking Singulair. Given that these symptoms may have been caused by other factors, it is not known if they are related to the use of Singulair. The physician should discuss these side effects with patients and/or their parents/guardians. Patients and/or their caregivers should be advised that if these symptoms occur, the attending physician should be informed.

Reducing the dose of systemic corticosteroids in patients receiving anti-asthma drugs, including leukotriene receptor blockers, was accompanied in rare cases by the appearance of one or more of the following reactions: eosinophilia, rash, worsening pulmonary symptoms, cardiac complications and / or neuropathy, sometimes diagnosed as Churg-Strauss syndrome, systemic eosinophilic vasculitis. Although a causal relationship of these adverse reactions with leukotriene receptor antagonist therapy has not been established, when reducing the dose of systemic corticosteroids in patients receiving Singulair, care must be taken and appropriate clinical monitoring should be carried out.

4 mg chewable tablets contain aspartame, a source of phenylalanine. Patients with phenylketonuria should be informed that each 4 mg chewable tablet contains aspartame in an amount equivalent to 0.674 mg phenylalanine. Singulair in the form of chewable tablets 4 mg is not recommended for patients with phenylketonuria.

Influence on the ability to drive vehicles and control mechanisms

This section does not apply to Singulair 4 mg chewable tablets as it is intended to treat
children from 2 to 5 years old. Thus, the information provided below refers to the active substance of the drug montelukast.

Singulair is not expected to affect the ability to drive and move vehicles.
mechanisms. However, individual reactions to the drug may be different. Some Side Effects
(such as dizziness and drowsiness) which have been reported to occur very rarely with the drug
Singulair may affect the ability of some patients to drive vehicles and move machinery.

Pregnancy and lactation

Clinical studies of the drug Singular with the participation of pregnant women have not been conducted. Singular should be used during pregnancy and during breastfeeding only in cases where the expected benefit to the mother outweighs the potential risk to the fetus or child.

During the post-registration use of the drug Singular, it was reported the development of congenital limb defects in newborns whose mothers took Singulair during pregnancy. Most of these women were also taking other asthma medications during pregnancy. A causal relationship between the use of Singulair and the development of congenital limb defects has not been established.

For patients with mild or moderate hepatic impairment, special dose selection is not required.

There are no data on the nature of the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (more than 9 points on the Child-Pugh scale).

Use in the elderly

For elderly patients special dose selection is not required.

Terms of dispensing from pharmacies

The drug is dispensed by prescription.

Terms and conditions of storage

The drug should be stored out of the reach of children, dry, dark place at a temperature of 15° to 30°C. Shelf life - 2 years.

Medical anti-asthma drug with a proven clinical effect. The main active ingredient is montelukast. The medicine has a high cost and is not always available for free sale. In the pharmacy network, you can buy analogues of Singulair with an identical substance in the composition.

Available in the dosage form of chewable tablets. Sold in different dosages, which allows you to create a convenient treatment regimen for patients of different ages.

Often used in pediatric practice. Allowed for children over the age of six. Rarely gives side effects.

Important! Patients should be warned by a doctor that Singulair is not an emergency remedy for the relief of acute bronchospasm. In any situation, you must have a beta-2-adrenergic agonist spray with you.

List of analogs Singulair

1. Almont (Russia). A qualitative analogue of the drug Singulair for children and adults. Prevents narrowing of the bronchi, as a reaction to provoking factors. Reduces the likelihood of acute asthma attacks and the need for bronchodilators.

Normalizes the functional parameters of the respiratory tract. Relieves bronchospasm. Reduces the painful susceptibility of the bronchial tree to external stimuli provoking bronchospasm.

Permissible children's age at admission is 2 years.

The cost of packing tab. 4 mg 28 pcs. - 750 rubles

2. Montelast (Russia). An effective analogue is cheaper than Singular. Provides significant relief to asthma patients. Reduces swelling of the bronchial mucosa. Shows high efficiency in the treatment of chronic allergic-polypous rhinosinusitis.

Prevents narrowing of the bronchi, as a reaction to physical activity, cold air, etc. In many cases, it allows you to reduce the amount of steroids taken needed to treat asthma.

Allowed for children from 2 years old.

Price tab.4 mg 28 pcs. - 825 rubles.

3. Singlon (Hungary). It is prescribed for the treatment and prevention of various forms of bronchial asthma, allergic diseases of the nasal mucosa.

This analogue of the drug Singulair is an excellent remedy for frequent relapses. hay fever. Helps to get rid of wheezing, removes "wheezing". Effective for a long treatment course of up to three months. It has a convenient form of reception - one tablet at bedtime.

In pediatric practice, it is prescribed from the age of 6.

Tablets 4 mg 28 pcs. - 870 rubles.

4. Montelukast (Russia). It is most often prescribed in combination with basic therapy to relieve symptoms of bronchial asthma.

Eliminates shortness of breath and attacks of asthmatic cough. Regular prophylactic intake reduces the likelihood of exacerbations.

Allowed to take from the age of six.

Tab. Chewing 28 pcs. 5 mg - 650 rubles.

5. Montelar (Switzerland). A qualitative analogue of Singulair tablets for the treatment of mild and moderate bronchial asthma. Inhibits the formation of secretions in the bronchi.

Long-term course reception significantly improves the performance of external respiration. Increases efficacy in asthma therapy hormonal inhalations, which allows progressively under medical supervision to reduce their dosage. An excellent tool for the prevention of exacerbations of allergies.

Admission allowed from the age of six.

Tab. chewable 4 mg 28 pcs. - 820 rubles.

6. Ektalust (Russia). Relieves symptoms of bronchial asthma. An effective remedy for long-term therapy. Relieves day and night manifestations of the disease.

Used in a combination treatment regimen along with bronchodilators medicines and inhalants glucocorticosteroids.

This analogue of the drug Singular is effective in the treatment of laryngotracheitis and allergic rhinitis.

It is prescribed for adults and adolescents from 15 years of age.

The cost of tablets 4 mg 14 pcs. - 470 r.

Many people suffering from bronchial asthma or seasonal rhinitis are familiar with the drug Singular. This is a truly effective medicine. It contains montelukast, a substance that quickly relieves spasms in the bronchi and eliminates swelling of the nasal mucosa. However, not all patients can use it due to the high price. Pharmacies sell cheaper, but equally effective analogues that have the same active ingredient.

Show all

Description of the drug

Medicines with the main active ingredient - montelukast - can relieve spasms. This substance inhibits bronchoconstriction processes. One of the most famous drugs based on it is Singulair. It suppresses bronchospasm at any stage and eliminates mucosal edema in allergic rhinitis. Even a small dose of the drug is effective.

After taking the drug, the lumen in the bronchi expands.

The medicine is made in Italy. Release form - chewable tablets. It refers to anti-asthma drugs: it prevents and relieves spasms that occur in the bronchi when inhaled LTD4 - cysteinyl leukotriene.

Singular is prescribed for both therapy and prevention in patients with asthma. The main directions of action of the drug:

treatment of patients with hypersensitivity to acetylsalicylic acid;
prevention of spasm during physical exertion;
prevention of the manifestation of day or night symptoms of the disease.

Seasonal rhinitis is also an indication for the use of the drug.

The effect of taking Singulair is visible already on the first day of its use. The tool can be used simultaneously with other drugs that expand the bronchi.

With all the obvious advantages, the tool also has a significant drawback - a high price. For a pack of 14 tablets, you will have to pay about 1000 rubles. The cost of tablets containing 10, 5 or 4 mg is practically the same. That is why many people think about the analogues of this drug.

Analogues

To date, pharmacies offer several drugs with a similar active ingredient. The difference between them is small, but with almost the same effect, they are several times cheaper.

Substitutes for Singulair include: Montelar, Singlon, Ektalust, Montelast.

Singlon

The effect of the use of this medicine is manifested already on the first day of admission. It is recommended to use the drug both during exacerbation of the disease and during remission.

Singlon is used to treat bronchial asthma.

This tool has a number of side effects, among which are suicidal thoughts and actions.

Detailed characteristics are presented in the table:

Parameter	Description
Manufacturer
Release form	Tablets 10 mg (pack of 14, 28 or 56 pieces)

Reception features	In exceptional cases, children 6-14 years old are allowed to take 5 mg per day. Adolescents from 15 years of age and adults are prescribed 10 mg per day, regardless of food intake. Do not use with other drugs that have the same active ingredient. The dose is the same for both men and women
Contraindications	It is forbidden to use during pregnancy and lactation. The drug is not recommended for children under 15 years of age
Side effects	bleeding; headache; sleep problems; thirst; stomach ache; tremor; hyperactivity; vomit: suicidal behavior

Montelar

Effective in the treatment of bronchial asthma, as well as in the treatment of allergic rhinitis. Not suitable for the relief of acute attacks.

Montelar can be taken in conjunction with inhaled corticosteroids and bronchodilators.

The drug has a large list of side effects, among which are mental disorders. The result of the use during pregnancy has not been studied, so expectant mothers should stop taking this medication.

Ectalust

Russian-made drug. After taking the maximum concentration of the drug in the blood is observed after 2 hours. The use of Ektalust enhances the effect of inhaled corticosteroids.

It is used for long-term treatment and prevention of asthma. It is effective in the treatment of asthma caused by intolerance to acetylsalicylic acid and in the relief of symptoms of allergic rhinitis.

The use of this drug is recommended for children under 15 years of age. Older patients should take other drugs based on montelukast.

In general, the medication is well tolerated. Side effects usually develop in a mild form. This is largely due to the reduced concentration of montelukast compared to other drugs.

Characteristic:

Parameter	Description
Manufacturer
Release form	5 mg chewable tablets (7, 14, 20 or 30 per pack)

Reception features	Take 60 minutes before or 2 hours after meals once a day. The tablet needs to be chewed. Dosage for children 2-5 years old - 4 mg 1 time per day. For children 6-14 years old, use 5 mg once a day. In the treatment of bronchial asthma, it is recommended to take it in the evening
Contraindications	Do not take with phenylketonuria and hypersensitivity to the components of the drug. Children under 2 years old, as well as pregnant women, the drug is prohibited.
Side effects	Anxiety; depression; insomnia; otitis; upper respiratory infections; cardiopalmus

Montelast

It is used for the treatment of asthma and its prevention, helps to relieve the symptoms of seasonal rhinitis. In acute spasms, it is ineffective.

After taking it, you should refrain from driving, as the use of the drug reduces attention and reaction speed.

The description is presented in the table:

Parameter	Characteristic
Manufacturer
Release form	Chewable tablets 5 mg (14, 28 pcs.). Tablets, film-coated, 10 mg (28, 98 pcs.)

Reception features	Directions for use: Take 1 hour before meals. The tablet must be chewed thoroughly. Doses: babies 2-6 years old - 4 mg 1 time per day - in the evening; children 6-14 years old - 5 mg 1 time per day, in the evening
Contraindications	Lactase intolerance. Phenylketonuria. Do not treat patients under 2 years of age
Side effects	Increased chance of bleeding; anaphylaxis; insomnia; pancreatitis; hives; muscle cramps

Conclusion

Each of the analogues of the drug Singulair has its own advantages and disadvantages:

1. In the price category, the best is Ektalust. This is a domestically produced medicine.
2. For the relief of acute spasms in the bronchi, the most effective is Singlon, but it should not be given to children under 2 years of age.
3. Each of the drugs has a wide range of side effects.
4. All medicines are prohibited during pregnancy and breastfeeding.
5. Montelast and Ectalust should not be taken with phenylketonuria and lactase intolerance.

Reception of this or that medicine should be prescribed by the attending physician. It is he who will select the most suitable drug in accordance with the characteristics of the patient.